Page 134 | Certara

Press Release

Certara Opens New China Office in Shanghai

Office will support rapid growth and collaboration with customers in China to accelerate biopharmaceutical R&D …

CertaraNovember 9, 2020

Video

D360 Overview

CertaraNovember 5, 2020

Publication

Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics

CertaraOctober 30, 2020

Blog

Preparing CDISC Submissions for China’s NMPA

China’s NMPA now accepts CDISC submissions. To support this initiative, Pinnacle 21 has released a…

CertaraOctober 30, 2020

White Paper

The Effects of COVID-19 on Stakeholder Engagement & Value Communication: Preparing for the New Normal

CertaraOctober 28, 2020

Video

PBPK modeling supports approval of breakthrough cancer drug

Pharmacyclics’ (now AbbVie) Imbruvica (ibrutinib) is an anticancer drug targeting B-cell malignancies. Leveraging the US…

CertaraOctober 23, 2020

Brochure

Simcyp® Drug Labels

CertaraOctober 23, 2020

Brochure

Simcyp PBPK Consulting Services

CertaraOctober 23, 2020

On-Demand Webinar

SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU

In this webinar, our experts provided an overview of the SNDS and the key working…

CertaraOctober 20, 2020

On-Demand Webinar

Best Practices for Small to Mid-Size Companies to Advance Drug Discovery Programs

Having the ability to scale with research needs is pivotal to success. Understanding when the…

CertaraOctober 12, 2020

Certara Opens New China Office in Shanghai

D360 Overview

Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics

Preparing CDISC Submissions for China’s NMPA

The Effects of COVID-19 on Stakeholder Engagement & Value Communication: Preparing for the New Normal

PBPK modeling supports approval of breakthrough cancer drug

Simcyp® Drug Labels

Simcyp PBPK Consulting Services

SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU

Best Practices for Small to Mid-Size Companies to Advance Drug Discovery Programs

Newsletter sign up

Quick links

Solutions

Contact